Trimebutine-d3 (hydrochloride)

• UNSPSC Description:

  Trimebutine-d3 hydrochloride is deuterated labeled Trimebutine (HY-B0380). Trimebutine is an opiate receptor agonist with antimuscarinic activity.

• Target Antigen:

  Isotope-Labeled Compounds; Opioid Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC(OC)=C(C(OC)=C1)OC([2H])([2H])[2H])OCC(CC)(C2=CC=CC=C2)N(C)C.Cl

• Molecular Weight:

  426.95

• References & Citations:

  [1]Kaneto, H., M. Takahashi, and J. Watanabe, The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. J Pharmacobiodyn, 1990. 13(7): p. 448-53.|[2]Roman, F.J., et al., Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J Pharmacol Exp Ther, 1999. 289(3): p. 1391-7.|[3]Hiyama, T., et al., Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J Gastroenterol Hepatol, 2009. 24(4): p. 537-46.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported